Tags Posts tagged with "$TWMJF"

$TWMJF

0 1385
Marijuana-Stocks-weed money wad (1)

Towards the end of June, the S&P 500 had been up almost 20% over the course of 12 months. With a historical rise on average of around 7% annually, the new average is something investors are excited about. If this looks like solid gains than you’re right, but take a look at the gains for the marijuana industry and you’ll be ecstatic. In some instances this industry has doubled or even tripled its value over the past 12 months.

Why are these stocks doing so well? One of the main reasons behind it is the rapidly changing public opinion on the plant. With more research than ever being conducted, the public is learning the truth behind marijuana’s health benefits. A 2016 poll from Gallup showed that favorability toward the legalization of marijuana hit an all time high of over 60%. As opinions get better, so do sales. Investors project the sales from U.S. legal marijuana will top $6.9 billion in 2016 and are expected to more than triple by 2021. All of this leads to a bright future for cannabis related investments.

Marijuana stocks are more profitable than ever as sales continue to grow. This does not mean one should forgo their usual research, if anything one should be extra careful because it is a new industry. That said, this is the time to diversify a portfolio to get some green with some green. Here’s four stock picks that should see profit this year.

1. Aphria
This is one of many Canadian medical marijuana producers and retailers as the Canadian marijuana industry has been around for much longer than its U.S. counterpart (legally that is).

Aphria (NASDAQOTH: APHQF) has been profitable for investors for an astounding five consecutive quarters. A new project is seeing the company enlarging its growing capacity to a 1 million square feet to help produce an estimated 75,000 kilograms of cannabis per year.

2. Canopy Growth Corp.
Yet another Canadian marijuana stock; this company currently has the highest market cap. Canopy Growth Corp. (NASDAQOTH: TWMJF) is on track to be profitable for this year. This company has benefitted from exporting some of its production overseas in places where cannabis is legal medically.

Canopy Growth also acquired Mettrum Health (which boosted its customer reach within Canada). In addition, they recently purchased 472,000 sq. ft. for its headquarters to expand grow capacity.

3. MedReleaf
This is another profitable stock called MedRelead (NASDAQOTH: MEDFF) (TSX:LEAF), which was the largest North American IPO to date. MedReleaf, like Aphria and Canopy Growth is a producer of medical cannabis for Canadian patients. The company recently raised over $74 million dollars from its IPO to fund its expansion in a facility located in Bradford, Ontario. Once the new facility is completed, MedReleaf says it will be capable of 35,000 kilograms of annual cannabis production.

4.Scotts Miracle-Gro
This emerging marijuana stock Scotts Miracle-Gro (NYSE: SMG) is expected to generate high profits for the 2017 fiscal year. The majority of Scotts’ business comes from various traditional lawn and garden care products. The other portion of business comes from hydroponics. As the traditional part of Scotts’ sees various ups and downs according to weather etc., their hydroponics section is growing very quickly up 17% from last year.

2 2567
Marijuana-Stock-cannabis-Split

The marijuana market is growing faster than most would believe and that’s creating a lot of interest in owning marijuana stocks. However, those willing to invest their money need to choose what marijuana stocks to buy carefully.

If you have thoughts about what marijuana stocks could be top stocks in 2018, you may want to consider the catalysts ahead for GW Pharmaceuticals (NASDAQ: GWPH), Canopy Growth (TSX: WEED)(NASDAQOTH: TWMJF), and Insys Therapeutics (NASDAQ: INSY).

What Makes These Marijuana Companies Valuable?

Unlike marijuana companies that are selling medical marijuana at dispensaries in states with medical marijuana laws on the books, GW Pharmaceuticals is pursuing Food and Drug Administration approval of a marijuana-based drug for epilepsy, and a decision from the FDA could happen early in 2018.

The drug — Epidiolex — has already delivered impressive efficacy in late-stage clinical trials, and if the FDA gives it a blessing, Epidiolex can sidestep the risk that Washington, D.C., starts enforcing federal laws prohibiting marijuana sales in states that have legalized it.

The U.S. marijuana market is getting bigger as more states pass pro-pot legislation, but it faces risks because federal laws still schedule marijuana as a Class 1 drug.

Instead of risking the Trump administration’s crackdown of marijuana markets in America, it may be a better bet to look north of the border to Canada, where medical marijuana has been legal since 2001 and recreational marijuana could become legal soon.

The biggest marijuana stock in Canada is Canopy Growth, the well-funded marijuana producer behind the popular marijuana brand Tweed. Canopy Growth has over $100 million on its balance sheet, and it did $40 million in marijuana sales last fiscal year. It’s using its deep pockets and cash flow to boost grow capacity, acquire smaller competitors, and establish itself as the go-to online marketplace for legal weed when recreational marijuana gets the green light in Canada.

It’s been a rough go for Insys Therapeutics investors. The company’s been under scrutiny ever since former executives were arrested on charges of illegally marketing its opioid spray Subsys for off-label use. A revolving door in the C-suite and ongoing investigations have done little to help the company stay focused on launching its marijuana-based drug, Syndros, and developing cannabidiol drugs like Epidiolex for tough-to-treat epilepsy.

The challenges have sent shares reeling, but Insys Therapeutics has a new CEO, and he’s saying all the right things.

0 4983
marijuana-stocks- benjamins

The marijuana industry is growing at a rapid pace, and investors have surely taken notice. Much more marijuana stocks have witnessed their valuations increase substantially, or maybe run even higher, over the trailing 12-month period.

Stemming from a 2016 Gallup poll and an April 2017 CBS News poll, the percentage of those who were receptive to seeing recreational cannabis legalized nationally which has surged to a respective 60% and 61%, both all-time highs. By comparison, Gallup’s 1995 poll showed just 25% approval for such a play, while the CBS News poll was a full 21-percentage-points lower just six years ago. The public wants change at the federal level, and investors are trying to beat that change by purchasing marijuana stocks.

The sale of legal marijuana has also risen. Investment firm Cowen & Co. is looking for $50 billion in legal annual cannabis sales by 2026, while a more recent report from Marijuana Business Daily implies that legal U.S. sales could triple between 2017 and 2021, to more than $17 billion. You’d probably struggle to find such consistent growth in any other industry or sector.

Which marijuana stock could hit $1 billion in sales first?

Yet, there are dozens of marijuana stocks to choose from, and they’re clearly not all going to be winners. The top performers, assuming marijuana remains legal in select states and that it gains broader approval in Canada and Mexico, are probably going to be the pot-based businesses that can really ramp up revenue and turn a healthy profit.

If there is a significant bench mark out there for marijuana stocks, it’s the $1 billion sales mark. The first cannabis company to hit $1 billion in sales will likely validate the industry. But which marijuana stock has the best chance at being first to $1 billion in annual sales?

1. GW Pharmaceuticals
Considered the most sensible choice is cannabinoid-based drug developer GW Pharmaceuticals (NASDAQ: GWPH), which also happens to be the largest pot stock by a mile in terms of market cap.

What makes GW Pharmaceuticals so unique is its currently experimental cannabidiol therapy Epidiolex, which hit its primary endpoint in a pivotal phase 3 trials for two rare types of childhood-onset epilepsy. In both its Dravet syndrome and Lennox-Gastaut syndrome trials, Epidiolex led to a statistically significant reduction in seizure frequency compared to the placebo.

The success of these studies puts the company on track to get Epidiolex approved by the Food and Drug Administration (FDA), though nothing is ever a guarantee when it comes to the FDA. Assuming some potential for label expansion, Epidiolex could very well hit $1 billion in peak annual sales, if not a tad higher.

2. Corbus Pharmaceuticals
Corbus Pharmaceuticals (NASDAQ: CRBP) is considerably more of a wildcard than GW Pharmaceuticals, but if one specific clinical trial goes its way, it could easily leap to $1 billion in annual sales.

Corbus’ pipeline consists of a solitary drug known as anabasum, which is a synthetic oral endocannabinoid-mimetic drug that binds to the CB2 receptors expressed on immune cells and fibroblasts. Its drug is being tested in four indications, but one stands out head and shoulders above the rest: cystic fibrosis (CF). There are few drugs to treat CF, and most that are FDA approved target a very specific mutation, making their impact limited within the CF community. Anabasum is believed to have a global anti-inflammatory effect, meaning it could be taken by most, or all, CF patients.

3. Canopy Growth Corp.
Another seemingly logical marijuana stock that could thrive is Canopy Growth Corp. (NASDAQOTH: TWMJF), a producer and retailer of medical cannabis products and oils in Canada. Medical weed has been legal in Canada since 2001.

Canopy Growth has been a busy bee of late on the acquisition front. It completed its acquisition of Mettrum Health earlier this year, and it acquired a 472,000 square foot facility that includes its current corporate headquarters.

Growth by acquisition gives the company immediate access to more medical marijuana patients and the ability to rapidly expand its growing capacity.

4. Aphria
One of Canopy Growth’s largest competitors in the Canadian medical marijuana producing and retail business is Aphria (NASDAQOTH: APHQF). Aphria has the distinction of being the most prominently profitable marijuana stock, with the company reporting five consecutive quarterly profits.

Unlike Canopy Growth, Aphria is doing things organically. It’s been funding expansions of its existing grow capacity, and is currently working on its most aggressive growth initiative to date, Phase IV.

5. Aurora Cannabis
And how can we forget Aurora Cannabis (NASDAQOTH: ACBFF), yet another of Canada’s medical cannabis producers and retailers. Aurora Cannabis has lagged its peers in recent profits due to its expansion-based spending.

Like Aphria, Aurora Cannabis is all about organic development. Aurora Cannabis has touted its Aurora Sky project, which will increase its cultivating capacity nearly ninefold, as the most technologically advanced and automated cannabis-grow facility in the world, when completed.

1 5874

Cannabis stocks have come down from their recent highs and this has raised some concerns after we ended 2016 on a high note.

2016 was a great year for the cannabis industry and we expect 2017 to build off this success. From Canada to Australia, the United States to Germany, the global cannabis industry continued to expand and the stage is set for growth for years to come.

The recent weakness has led to an influx of questions pertaining to the top cannabis investment opportunities and we want to highlight 7 cannabis stocks that investors should watch during 2017.

Seven Cannabis Stocks to Watch

1. GW Pharmaceuticals (GWPH): We continue to view GWPH as the top long-term biotech investment levered to the cannabis industry and we expect to see a VERY STRONG second half of the year. We are favorable on the long-term outlook due to its deep pipeline of products in advanced stages of clinical trials, its strong balance sheet, and its favorable Wall Street coverage.

2. Zynerba Pharma (ZYNE): We consider the company to be one of the most undervalued biotech investment opportunities. Zynerba is focused on developing treatments from synthetic cannabis and the average Wall Street price target offers almost 100% upside to current levels.

3. Canopy Growth (WEED.TO) (TWMJF) continues to be the leader in the Canadian medical cannabis industry and view the company as one the best opportunities within the cannabis industry. The shares have been trending lower and we view this weakness as a great opportunity to buy into a high-quality cannabis producer with a global footprint.

4. Emblem Corp. (EMC.V) (EMMBF) has been trending so far this year and the shares are down 30% during this time. Despite the recent weakness, we are bullish on the company’s opportunity due to its attractive business model, its proven management team, its sound financial structure, its strong balance sheet, and its leverage to growth trends in the cannabis sector

5. After securing a potentially highly lucrative licensing contract, InMed Pharmaceuticals, (IN.CN) (IMLFF) looks even better positioned to benefit for positive tailwinds facing the global cannabis industry. InMed is a pre-clinical biopharmaceutical company that is focused on the research and development of novel and cannabinoid-based therapies in Canada. The company has a strong pipeline of products in various stages of FDA testing and is developing various drugs for diseases, such as ocular, pain and inflammation.

6. VPR Brands, LP, (VPRB) is a stock to watch as it is levered to several growth trends within the global cannabis industry. The shares have pulled back and we see upside to current levels. In 2016, VPR acquired Vapor Corp’s wholesale operations and assets for a significant discount and recent announcements show that VPR has executed on and monetized this acquisition. We view this as a very attractive growth story that is undervalued by the street.

7. Vinergy (VIN.CN) (VNNYF) has been one of the most interesting and exciting stories to watch over the last six months and we see significant upside to current levels. The shares have fallen more than 33% in the last month and we find them to be attractive due to the number of catalysts for growth over the next year.

Disclaimer:
Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals.Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 90 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $45,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (IMLFF, VPRB, VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

1 5359
marijuana-stocks-cannabis-canadian_flag

Last month, on October 3, 2016, we published an article titled Past, Present, & Future of Canadian Marijuana Stocks where we expressed our bullish sentiment on the Canadian marijuana sector and identified a list of stocks to consider. In the article, we named 6 companies to focus on. Within one month of publishing the article, those 6 stocks have seen combined 480% in total gains as of November 2nd, 2016. This article would have been out a week ago if our new intern knew how to hit the publish button correctly. Regardless, the gains and the charts do not lie as they tell the tale of the ticker tape.
The Canadian government is planning to legalize cannabis in spring 2017 and the number of Canadian medical marijuana patients is expected to more than double. This will tilt the supply and demand scale for medical marijuana largely in favor of demand. We do not believe this recent rally to be just a pre-election “hype rally.” This is the coming out party for an industry with an immensely bright future and staying power.
Licensed medical cannabis producers have raised more than $100 million in the past couple months to be used to support growth initiatives like mergers and acquisitions and facility expansions to better meet the increased demand. The investment opportunities in the legal cannabis industry have proven extremely lucrative to informed investors. Let’s take a look at the 6 companies we highlighted in our October 3rd article to see how they are doing today and where they could go from here.
1. Canopy Growth Corporation (CGC.TO)(TWMJF)

pic1

 

 

Canopy Growth is the largest legal medical marijuana producer in Canada and has been one of the most attractive investment opportunities in the cannabis sector since going public in 2014. CGC.TO hit a high of $7.35 on October 20th for an 80.5% gain from our initial article publication. The stock closed trading today at $6.55, still up 61%. TWMJF (the US OTC listing) still sits up 58% today.

Canopy Growth is the medical marijuana industry leader. Aside from individual news announcements, expect other marijuana companies to follow the strength and/or weakness of CGC.TO. After a healthy pull-in, the stock held support around $5.50 and remains in a strong uptrend.

2. Aurora Cannabis (ACB.CN)(ACBFF)

pic2

Aurora Cannabis is one of the fastest growing licensed medical cannabis producers in Canada. One thing to know about them is that they recently did a private placement for $20,000,000 and ended up being over-subscribed by a few million dollars. They have one of the industry’s more impressive facilities and is partly why we added Aurora to our Focus List in June 2016. Since July of 2016, ACBFF is up roughly 125%. And since our article publication on October 3rd, ACBFF gained as much as 78% and closed trading today around $1.66, still up nearly 57%.

ACBFF is forming a bullish pennant pattern that would trigger a long through the $1.77 area or a sell below the $1.50 area. A breakdown of the pattern could see ACBFF test the gap it put in place on October 5th. However, a healthy consolidation in this range would give the moving averages time to catch up while the stock takes a breather before a possible move higher into $2.00 land.

3. Aphria Inc. (APH.V)(APHQF)

pic3

Aphria showed the smallest gain potential of all the companies listed in our October 3rd article. A max 17% gain was possible while APH closed trading today at $3.80, still up 10%.

APH.V has put in a double top at $4.00 that would act as a trigger long if broken to the upside. Support is in place around $3.30 after being tested multiple times and holding over the past month. A break below this support could see Aphria test its next support area around $3.00.

4. OrganiGram Holdings (OGI.V)(OGRMF)

pic4

Organigram is the second largest licensed producer in Canada and was the first to report positive cash flow. Organigram could be considered the second industry leader behind Canopy Growth so it is no surprise to see the two share very similar chart patterns. OGI.V hit a high of $3.11 on October 19th for a 75% gain from our article publication and closed trading today at $2.76, still up 55%.

Like CGC.TO, Organigram remains in an uptrend. Support was put in around the $2.30 area after a healthy pull-in. Look for OGI.V and CGC.TO to show strength and weakness together. It would be rare for one to show strength while the other weakness (unless for an individual press release good or bad).

5. Arcturus Growthstar Technologies (AGS.CN)(AGSTF)

pic5

Arcturus Growthstar Technologies is a company that may play a huge part in the expansion of the Canadian cannabis market and its ability to meet the increased demand. Their Controlled Environment Agriculture technology helps producers minimize land, water, and energy output while increasing crop turnover and capacity.

We also published a Connect the Dots piece on AGSTF on October 4th to introduce our readers to a new company that we believed was worth considering. The stock gained a remarkable 180% in just three days before pulling back in to still be up 34%. For those unfamiliar with Arcturus, we recommend going back and reading our Connect the Dots piece published on October 4th.

It’s important to discuss why such a sharp pullback after the 180% run. And we believe there to be a couple reasons.

➢ The stock is a very new issue and, therefore, does not have as much of a trading history as some of the other companies on this list. The trading float is also much smaller than the Canadian companies that came public in 2014 or sooner. This can sometimes result in over exaggerated or over extended price movements in both directions because of lack of stock available in the open market.

➢ The Company had a million dollars of warrants exercise at $0.15 to raise additional capital to support their rapid growth and expansion. Although it brought cash to the company, it added pressure to the market that aided in the sharp pull-in. But with that exercise now behind them, Arcturus can focus on putting that money to work.

Don’t forget, in October 2015, one year ago, Organigram traded for less than $0.30 a share, too. Fast forward to October 2016 and the stock now trades for $2.75 a share. Good management can build shareholder value pretty quickly when appropriating funds correctly and progressing through their business plan. And the management team behind Arcturus is one of the main reasons why we decided to issue a Connect the Dots piece on the company.

6. Cronos Group (formerly PharmaCan Capital Corp.) (MJN.V)(PRMCF)

pic6

Cronos Group is an investment firm and holding company for Licensed Producers under Canada’s Marihuana for Access to Cannabis for Medical Purposes Regulations (“ACMPR”). With interests in five licensed producers and three license applicants, Cronos Group is focused on building iconic brands providing patients with compassionate, personalized care. The stock hit a high of $1.35 on October 6th for a 45% gain from our article publication and currently still sits up 29%.

Similar to Aurora Cannabis, Cronos has developed a bullish pennant pattern. The $1.30 area would be a trigger long while the $1.13 area a trigger sell. A breakout could see MJN.V run to the $1.60 area while a breakdown would most likely retest the $1.00 mark, maybe lower.
Conclusion

The timing of our article titled Past, Present, & Future of Canadian Marijuana Stocks was spot on. We nailed breakout points in most of the major Canadian cannabis companies. After publication, the 6 stocks highlighted gained a combined total of 480% and each one remains higher today.

As we mentioned in the article, we believe the Canadian market to be much further along in development than the US market; although the US market is making major strides that we will discuss in a future article. The overall marijuana industry is experiencing a strong rally, both in the US and Canada. And we believe the companies discussed in this piece to have long-term investment potential, not just a quick trade.

0 3706
marijuana

Cannabis stocks continue to run higher and this rally has shown no signs of stopping with the election less than a month away.

Legal cannabis is coming and the election will be one of the most significant event-driven catalysts for cannabis stocks as a record number of states are voting on some form of legal cannabis.

With California voting on legal recreational marijuana and a legal medical marijuana initiative on the ballot in Florida, the elections represent a watershed moment for the cannabis industry.

Cannabis Ballot Initiatives Ahead in the Polls

Not only are a record number of states voting on legal cannabis, but the polls show that legal cannabis is leading in every state where there is such an initiative on the ballot.

The legal cannabis industry has gained a lot of ground in the last two years but we are still in the first inning of a multi-decade growth cycle.

The cannabis industry is the fastest growing industry in the world and Wall Street has taken notice of this. We believe that the elections will be the tipping point for the cannabis industry and if cannabis is legalized in California (recreationally) and Florida, we expect to see a lot more money from Wall Street enter the sector.

How to Capitalize on the Cannabis Movement

From an investor standpoint, there are several ways to capitalize on this opportunity but the best and easiest avenue is through investing in publicly traded companies.

Although many cannabis stocks have already had remarkable rallies, we think this is just the beginning and we continue to see value in many cannabis stocks. Some stocks you should keep an eye on include:

GW Pharmaceuticals (GWPH): Continues to be our favorite investment in the cannabis sector and we are even more favorable on GWPH after Goldman Sachs initiated coverage with a Buy rating and $189 price target. GW Pharma has the most Wall Street coverage in the cannabis sector, it has the best pipeline of prodcuts, and it continues execute and delivery value to its shareholders.

Canopy Growth Corp (CGC) (TWMJF): We are favorable on Canopy Growth due to the following reasons: 1) its leading Canadian market share, 2) its management, which continues to execute on initiatives and create value for shareholders, 3) its partnerships and recent acquisitions, and 4) its growth potential. We are also favorable on

MassRoots (MSRT): The shares have rallied more than 66% since September 30th, which was when MSRT traded at a new all-time low of $0.38. Technical420 remains favorable on MSRT at current levels and our investment thesis is based off the company being able to grow revenues while keeping its costs the same. We expect to the company to issue an update highlighting its recent improvements from a fundamental standpoint soon and we see upside to current levels.

Authored By: Michael Berger

0 6199

The Canadian medical marijuana industry continues to be a major bright spot in the cannabis sector as the industry exits the fringes and enters the mainstream. The main catalyst in our estimation is a simple, yet integral one; successful management teams. These management teams have done what many companies in the United States have been unable to do by executing on a business model that has stayed the course (rather than change directions every six months). Beyond good management teams and the execution of business models there have been a few Canadian companies have seen the forest through the trees ahead of some landmark decisions. We have seen public company Tweed Inc (OTC: TWMJF TSX: CGC) and private cultivation juggernaut Tilray do exceptionally well by sticking to their business models and taking measured risk ahead of legislation. One the biggest developments in 2015 was the victory by Justin Trudeau and the Liberal Party as they will make cannabis legalization a priority. The outcome of the campaign was a huge victory for the Canadian cannabis industry and it has already severed as a catalyst for stocks leveraged to the expansion of the cannabis industry.

Event Driven Equities

The Canadian government’s plan to legalize cannabis in spring 2017 has made several licensed medical cannabis producers attractive investment opportunities to institutional investors, hedge funds, and investments banks. Money is being invested in not just cultivation, but compliance, infrastructure, efficiency applications and Grow Tech.

In the last two months, licensed medical cannabis producers have raised more than $100 million of debt and equity, which will be used to support growth initiatives like land acquisitions, company roll-up acquisitions, facility expansions, etc all to service the estimated 40,000 medical patients and other ancillary services needed for Canadian expansion. These numbers will likely increase as the Trudeau administration likely wants to take cannabis recreational nation-wide which will benefit, not just some of the usual suspects like Tweed & Tilray, but other companies in the Canadian Cannabis following some of the sector leader’s models and expanding on them.

Canopy Growth Corp (CGC) (TWMJF): Canopy Growth is the largest legal medical marijuana producer in Canada and it has been one of the most attractive investment opportunities in the cannabis sector since going public in 2014. The US price is up 50% since July of this year with a 52 week high of $3.23USD with a 9/30/2016 close price of $3.07.

CGC.TO

 

Aurora Cannabis (ACB) (ACBFF): Aurora Cannabis is one of the fastest growing licensed medical cannabis producers in Canada. One thing to know about them is that they recently did a private placement for $20,000,000 and ended up being over-subscribed by a few million dollars. Any company can raise money, but if you’ve ever looked into their investor deck or seen the facility they have built out it’s hard to not be impressed, which is why we added it to our focus list in June of 2016. Since July of 2016, ACBFF is up roughly 125%.

ACBFF

Other notable Publicly Traded Cultivators in Canada:

Aphria, Inc. (APH) (APHQF): Aphria is a licensed medical marijuana producer in Canada and the company recently announced a profitable fourth quarter.

APH

OrganiGram (OGI) (OGRMF): OrganiGram was the first licensed producer to report to be cash flow positive and the company is the second largest licensed producer in Canada.

CCI.V

The Newcomers You Should Be Watching:

Arcturus GrowthStar Technologies Inc: (CSE: AGS, OTC: AGSTF) Arcturus is a company focused on acquiring and developing technologies in order to position itself -as the leading play in the Controlled Environment Agriculture (CEA) market. AGS provides CEA systems that utilize minimal land, water and energy regardless of climate

AGSTF

 

Arcturus GrowthStar Technologies Inc. (OTC: AGSTF) is a relatively new Canadian issue dual-listed on the OTC that is beginning to garner investor interest. Recent increase in trading activity could be foreshadowing a much larger increase in share price as the entire Canadian marijuana market experiences a bull rush. Companies with good management and solid business plans are being acquired by retail and institutional investors alike. Arcturus is one to keep an eye on.

Pharmacan Capital Corp (TSX: MJN, OTC: PRMCF)

Pharma Can Capital Corp is a holding company for Licensed Producers under Canada’s Marihuana for Access to Cannabis for Medical Purposes Regulations (“ACMPR”). With interests in five licensed producers and three license applicants, PharmaCan is focused on building iconic brands providing patients with compassionate, personalized care. We recently met them at the Lift Cannabis Expo in Vancouver and were impressed by the medicine they are producing for patients and the genius of hiring Canadian cannabis advocate Matt Mernagh to spearhead the marketing of the company. I view Matt Mernagh as the ultimate checks and balances as he has been one of Canada’s biggest champions of legalization and he would never stand behind medicine that wasn’t top notch.

MJN.V

 

 

 

 

 

 

 

 

 

This email is for ‘wolfofweedstreet@gmail.com‘ You have received this email because you are subscribed to MarijuanaStocks.comPursuant to an agreement between MAPH and ARCTURUS GROWTHSTAR, we were hired for a period of 30 days to publicly disseminate information about (AGSTF) including on the Website and other media including Facebook and Twitter. We are being paid $37,500 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (AGSTF), which we purchased in the open market. We plan to sell the “ZERO” shares of (AGSTF) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (AGSTF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.Unsubscribe | To contact us please reply to this email | PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMERMarijuanaStocks.com | |

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements